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Comment on: Tumour necrosis factor inhibitor
survival and predictors of response in axial
spondyloarthritis—findings from a United
Kingdom cohort
SIR, We read with interest the report by Yahya et al. [1]
on tumour necrosis factor inhibitor (TNFi) survival and
predictors of response in axial spondyloarthritis (axSpA)
patients treated in a real-life setting in the UK, where no
sex differences were identified impacting these out-
comes. Data over the last decade suggest sex-attribut-
able differences in disease features, clinical outcomes
and treatment response in axSpA, with a longer diag-
nostic delay [2], older age at disease onset [3] and
higher number of affected first-degree relatives [4] in
females. These findings suggest that a higher genetic
load is needed in order to develop the disease in
females than in males [5]. Furthermore, women appear
to have a higher burden of disease [3], reduced re-
sponse to TNFi [6, 7] and higher switching rate [8].
Characterization of these differences is essential for a
better understanding of the disease trajectory in order to
deliver optimal personalized medical management.
Here, we report our experience from a single tertiary
centre in a large teaching hospital, exploring the role of
sex in treatment response, drug survival and switching
rate in a cohort of biologic-treated axSpA patients.
As part of service development and to comply with
mandatory audit according to National Health Service
governance systems, we conducted a retrospective
evaluation of anonymized data using the Leeds
Spondyloarthritis Service database. Subjects were eligi-
ble if they had a physician-verified diagnosis of radio-
graphic axSpA fulfilling the modified New York criteria
(mNYC) for AS and if they received the first TNFi be-
tween 1999 and 2017. Exclusion criteria included being
prescribed the first TNFi for a diagnosis other than AS,
not having TNFi as the first biological (switch to another
biological class was allowed), having a follow-up
<12 months or participating in the placebo arm of a clin-
ical trial. In compliance with National Institute for Health
and Care Excellence guidance, all subjects had a
BASDAI4 at initiation of the first TNFi. Information on
disease characteristics, patient-reported outcomes for
disease activity (BASDAI), function (BASFI) and pain
(visual analog scale) were available at baseline.
Treatment response was evaluated by the improvement
of 50% in BASDAI (BASDAI50) after 3–6 months (first
evaluation) and 1–1.5 years (second evaluation) of
treatment. Kaplan–Meier curves were calculated to de-
scribe drug survival, and the log-rank test was used to
test for differences between the sexes. Discontinuation
was classified as attributable to non-response, intoler-
ance (including adverse events) or other reasons (patient
decision, death, finished a trial), and the frequency of
switching between biologicals was calculated by sex for
each drug. All statistical analyses were done in SPSS
software (SPSS Statistics, version 21).
Data from 280 patients (75 females and 205 males)
were available for analysis (Supplementary Table S1,
available at Rheumatology Advances in Practice online).
Significant differences between the sexes were ob-
served, with females having a higher prevalence of IBD
at the baseline (21.3 vs 9.8%; P¼ 0.010) and family his-
tory of SpA (61.4 vs 41.8%; P¼ 0.013) than males. No
other sex differences were observed with regard to age
at diagnosis, disease onset, delay in diagnosis, symp-
tom duration, patient-reported outcomes or baseline
CRP. At the first evaluation, more females reached
BASDAI50, but this was not sustained at the second
evaluation (Supplementary Tables S2 and S3, available
at Rheumatology Advances in Practice online). In con-
trast to the findings of Yahya et al. [1], females showed
a significantly shorter drug survival for the first
drug compared with males (median, 34.4 vs
91.6 months; P < 0.001), but this difference was not sig-
nificant for the total number of biological drugs (Fig. 1).
More females than males discontinued treatment owing
to intolerance (Supplementary Figure S1, available at
Rheumatology Advances in Practice online), which
includes adverse events (81.3 vs 48.6%). A total of
40.4% of patients switched to a second drug, with more
females than males (53.3 vs 35.6%) mainly because of
non-response. Our cohort comprises solely AS patients,
with a switching rate similar to the DANBIO registry [8]
but higher than that reported by Yahya et al. [1],
probably reflecting locally agreed commissioning
pathways.
There are a number of limitations to our report, such
as the retrospective design, small sample size and miss-
ing BASDAI data, which lead to a low statistical power;
however, these data provide one of the longest observa-
tional reports to date, with some patients being followed
up for 19 years.
In conclusion, in our cohort there was no difference in
disease burden between sexes at the time of TNFi initia-
tion, although females had a higher prevalence of IBD
and more relatives with SpA, as shown by other groups.
Although no sex difference in treatment response was
seen, a higher switching rate and shorter drug survival
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males. The majority of patients, of both sexes, remained
on biological treatment (81.1%) for a median treatment
duration of 6.3 years. These data add to the body of evi-
dence of real-life response to TNFi in radiographic
axSpA.
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FIG. 1 Survival rates of first TNFi and all biologicals stratified by gender
(A) First TNFi. (B) All biologicals.
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